In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection
Keyword(s):
ABSTRACT Rilpivirine (RPV), dapivirine (DPV), and MIV-150 are in development as microbicides. It is not known whether they will block infection of circulating nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant human immunodeficiency virus type 1 (HIV-1) variants. Here, we demonstrate that the activity of DPV and MIV-150 is compromised by many resistant viruses containing single or double substitutions. High DPV genital tract concentrations from DPV ring use may block replication of resistant viruses. However, MIV-150 genital tract concentrations may be insufficient to inhibit many resistant viruses, including those harboring K103N or Y181C.
2006 ◽
Vol 80
(9)
◽
pp. 4440-4446
◽
2009 ◽
Vol 53
(5)
◽
pp. 1739-1746
◽
2000 ◽
Vol 44
(1)
◽
pp. 123-130
◽
2004 ◽
Vol 48
(12)
◽
pp. 4680-4686
◽
2006 ◽
Vol 70
(2)
◽
pp. 66-74
◽
2002 ◽
Vol 76
(20)
◽
pp. 10546-10552
◽
2005 ◽
Vol 49
(11)
◽
pp. 4465-4473
◽
2010 ◽
Vol 55
(1)
◽
pp. 42-49
◽